.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AE30_InsulinDegludecAndLiragl.InsulinDegludecAndLiragl

Information

name:InsulinDegludecAndLiraglutide
ATC code:A10AE30
route:subcutaneous
n-compartments2

Combination of insulin degludec, an ultra-long-acting basal insulin analogue, and liraglutide, a GLP-1 receptor agonist. Used in the management of type 2 diabetes mellitus to improve glycemic control. Approved by regulatory agencies in many countries under the brand name Xultophy.

Pharmacokinetics

Pharmacokinetic parameters estimated for healthy adults based on published single-agent studies and product information. No single-population PK study directly available for the fixed combination product.

References

    Revisions

    Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos